Birth after TESE–ICSI in a man with hypogonadotropic hypogonadism and congenital adrenal hypoplasia linked to a DAX-1 (NR0B1) mutation by Frapsauce, C. et al.
CASE REPORT Reproductive genetics
Birth after TESE–ICSI in a man with
hypogonadotropic hypogonadism and
congenital adrenal hypoplasia linked to
a DAX-1 (NR0B1) mutation
C. Frapsauce1, C. Ravel1, M. Legendre2, M. Sibony3, J. Mandelbaum1,
B. Donadille4, J.C. Achermann5, J.-P. Siffroi2,6, and
S. Christin-Maitre4,6,*
1UPMC, AP-HP, Ho ˆpital Tenon, Service de Biologie de la Reproduction, 75020 Paris, France
2AP-HP, Ho ˆpital Trousseau, Service de
Ge ´ne ´tique et d’Embryologie Me ´dicales, 75012 Paris, France
3AP-HP, Ho ˆpital Tenon, Service d’Anatomopathologie, 75020 Paris, France
4Service d’Endocrinologie, Ho ˆpital Saint-Antoine, AP-HP, Centre de maladies endocriniennes rares de la croissance CMERC, 75012 Paris,
France
5Developmental Endocrinology Research Group, Clinical & Molecular Genetics, UCL Institute of Child Health, University
College London, London WC1N 1EH, UK
6ER9, ge ´ne ´tique de la reproduction, Faculte ´ de me ´decine Pierre et Marie Curie,
University Paris VI, France
*Correspondence address. Service d’Endocrinologie, Ho ˆpital Saint-Antoine, AP-HP, Centre de maladies rares de la croissance (CMERC),
184 rue du faubourg Saint-Antoine, ER-9 Universite ´ Paris VI, 75012 Paris, France. Tel: +33-1-49-28-24-00; Fax: +33-1-49-28-31-95;
E-mail: sophie.christin-maitre@sat.aphp.fr
Submitted on July 4, 2010; resubmitted on November 30, 2010; accepted on December 3, 2010
abstract: DAX1/NR0B1 mutations are responsible for X-linked congenital adrenal hypoplasia (AHC) associated with hypogonadotropic
hypogonadism (HH). Few data are available concerning testicular function and fertility in men with DAX1 mutations. Azoospermia as well as
failure of gonadotrophin treatment have been reported. We induced spermatogenesis in a patient who has a DAX1 mutation (c.1210C.T),
leading to a stop codon in position 404 (p.Gln404X). His endocrine testing revealed a low testosterone level at 1.2 nmol/l (N: 12–40) with low
FSH and LH levels at 2.1 IU/l (N: 1–5 IU/l) and 0.1 IU/l (N: 1–4 IU/l), respectively. Baseline semen analysis revealed azoospermia. Meno-
tropin (Menopur
w:150 IU, three times weekly) and human chorionic gonadotrophin (1500 IU, twice weekly) were used. After 20 months of
treatment, as azoospermia persisted, bilateral multiple site testicular biopsies were performed. Histology revealed severe hypospermatogenesis.
Rare spermatozoa were extracted from the right posterior fragment and ICSI was performed. Four embryos were obtained and, after a frozen–
thawed single-embryo transfer, the patient’s wife became pregnant and gave birth to a healthy boy. We report the ﬁrst case of paternity after
TESE–ICSI in a patient with DAX1 mutation, giving potential hope to these patients to father non-affected children. Furthermore, this case
illustrates the fact that patients with X-linked AHC have a primary testicular defect in addition to HH.
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Introduction
DAX-1 [Dosage sensitive sex-reversal, Adrenal hypoplasia congenita,
on the X chromosome gene 1], alternatively called NR0B1,i s
a gene that encodes an orphan member of the nuclear hormone
receptor family (Zanaria et al., 1994). The protein translated from
this gene, called DAX-1, is essentially expressed in tissues involved
in steroid hormone production and reproductive function such
as the adrenals, hypothalamus and pituitary, as well as the testes
(Guo et al., 1995). Clinically, NR0B1/DAX1 mutations are responsible
for X-linked congenital adrenal hypoplasia (AHC) (MIM # 300200)
associated with hypogonadotropic hypogonadism (HH) (Lin et al.,
2006). In mice, Nr0b1 null homozygous male mice have adrenal insuf-
ﬁciency as well as testicular disorganization, dilated seminiferous
tubules and failed spermatogenesis (Park et al., 2005). The dilated
tubules in the adult reﬂect impaired testis cord morphogenesis
during embryonic development (Meeks et al., 2003). Histological
examination revealed a progressive degeneration of seminiferous
tubule epithelium, hyperplasia of Leydig cells and sloughing of germ
cells. A Sertoli-cell-speciﬁc expression of a DAX1 transgene is sufﬁcient
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deﬁcient mouse (Jeffs et al., 2001).
Relatively few data are currently available concerning the testicular
function and fertility of men with X-linked AHC harbouring DAX1
mutations. Some cases of azoospermia as well as failure of gonado-
trophin treatment have been described (Mantovani et al., 2002;
Brown et al., 2003; Ozisik et al., 2003; Seminara et al., 1999). Oligo-
spermia has been reported in a rare case of late-onset AHC
associated with a partial loss-of-function mutation (Tabarin et al.,
2000). The failure of the gonadotrophin treatment described was
judged on semen quality, and open testicular biopsy had not been
attempted previously in order to treat male infertility.
We report the ﬁrst birth of a child after a successful assisted repro-
ductive technique (ART) in a man with classic AHC and HH due to a
DAX1 mutation, using TESE–ICSI.
Case report
Our patient presented with primary adrenal insufﬁciency at the age of
3 weeks, diagnosed on account of major dehydration. He was treated
with hydrocortisone and 9-alpha-ﬂudrocortisone in order to restore
glucocorticoid and mineralocorticoid deﬁciencies. He was referred
to our unit at the age of 19 years because of hypogonadism. He
had no history of cryptorchidism and his testes were small, 6 ml on
each side. His penis was 6 cm in length and he had sparse pubic
hair. His sense of smell was normal and he was shaving twice a
month. His puberty was evaluated at P2 Tanner’s stage. Bone densi-
tometry revealed osteopenia with a T-score of 22.5 DS at the
lumbar level. His bone age reached 15 years. Hius testosterone
level was low 1.2 nmol/l (N: 12–40). Baseline FSH and LH levels
were 2.1 IU/l (N: 1–5 IU/l) and 0.1 IU/l (N: 1–4 IU/l), respectively.
A GnRH test (100 mg, subcutaneous) was conducted. The FSH and
LH peaks reached 3.1 and 0.9 UI/l, respectively. LH and FSH pulsati-
lity was studied over a 4-h period. No LH nor FSH pulses could be
detected. Prolactin and FT4 levels were normal at 14.6 pg/ml
(N: 5–10) and 17.2 pmol/l (N: 10–23), respectively. Pituitary MRI
was normal. An adrenal scan revealed an atrophic left adrenal. The
right adrenal could not be visualized. In summary, he presented with
adrenal insufﬁciency associated with HH. He is an only child and a
sporadic case in his family.
Considering the association of adrenal insufﬁciency and HH, genetic
testing of the NR0B1/DAX1 gene was conducted, after obtaining
informed consent according to the French ethics law. As shown in
Fig. 1, a change in nucleotide sequence (c.1210C.T) was identiﬁed,
leading to a stop codon in position 404 (p.Gln404X). This mutation
in our patient is found in a large cohort of ACH patients (Lin et al.,
2006).
Hypogonadism was treated by testosterone enanthate (Androtar-
dyl
w: 250 mg intramuscularly, every 3 weeks). Six years later, as he
desired paternity, a semen analysis was performed, which revealed
azoospermia. Semen volume and semen pH were found to be
normal. Spermatogenesis was therefore induced by gonadotrophins
using menotropin (Menopur
w:150 IU of FSH and 150 IU of LH,
three times weekly) and human chorionic gonadotrophin (hCG:
1500 IU, twice weekly). One month later, his testosterone level
reached 4 ng/ml. The treatment doses remained constant. After 20
months of treatment, testis volume reached 11 and 12 ml, for his
right and left testis, respectively. However, azoospermia persisted.
Consequently, bilateral testicular biopsies were performed. It was a
blind, multiple-site biopsy. Very few spermatozoa were extracted
from the right posterior fragment. Three straws were cryopreserved,
each containing 100 motile spermatozoa. Histological examination
revealed severe hypospermatogenesis. The diameter of the
seminiferous tubules was either normal or reduced. Tubules
were limited by a thickened basement membrane and contained
mostly Sertoli cells and a few germ cells arrested at the spermatocyte
stage (Fig. 2).
His wife had been stimulated using triptorelin (Decapeptyl
w) and
recombinant FSH (Gonal-F
w 150 IU) for 10 days. As a result, 11
oocytes were obtained, seven of them being mature. ICSI was per-
formed using all the cryoconserved straws. No motile spermatozoa
were recovered after thawing, and thus pentoxifylline (1 mg/ml) was
used. Indeed, after the freezing–thawing process, the percentage of
motile testicular spermatozoa is usually low, with a weak motility
making the selection of live spermatozoa difﬁcult. Pentoxifylline was
found to signiﬁcantly increases the motility of spontaneously immotile
epididymal and testicular spermatozoa and allows fertilization, preg-
nancy and birth after ICSI (Terriou et al., 2000). Selection of viable
spermatozoa is therefore easier. Four embryos were obtained: two
Day-2 embryos were transferred and the remaining two were cryo-
preserved. No pregnancy followed. The following cycle, only one
embryo remained viable after thawing and was used in a single-embryo
transfer during a stimulated cycle. After this procedure, the patient’s
wife became pregnant and gave birth—9 months later, by Caesarean
section—to a healthy boy.
Discussion
We report the ﬁrst case of a child born after TESE–ICSI, with the
sperm induced by gonadotrophin treatment, in a man with classic
X-linked AHC due to a nonsense mutation in NR0B1/DAX1.
Our patient had a severe clinical phenotype of neonatal adrenal
insufﬁciency associated with hypogonadism, rather than a delayed
onset or milder form of AHC (Brown et al., 2003; Ozisik et al.,
2003). In this case, the c.1210C.T nucleotide change is predicted
to result in a p.Q404X nonsense mutation located in the C-terminal
ligand-like binding domain of the protein (Lin et al., 2006). Missense
mutations within this domain have already been shown to induce
lower activity of DAX1 (Tabarin et al., 2000) and the p.Q404X
change is likely to escape nonsense-mediated decay and to result in
a truncated protein product lacking an AF-2 domain (Fig. 1C). There-
fore, the nonsense mutation in our patient was considered to be
responsible for his severe phenotype.
Gonadal defects in men carrying DAX1 mutations have been
described in several cases (Caron et al., 1999; Tabarin et al., 2000;
Achermann et al., 2001; Mantovani et al., 2002). In our patient, a
few testicular spermatozoa were obtained from a testicular biopsy
after a long period of treatment using exogenous gonadotrophins. In
the past 20 years, such treatments have been used to induce sperma-
togenesis in men with isolated HH (Finkel et al., 1985; Bu ¨chter et al.,
1998; European Metrodin HP Study group, 1998; Matsumoto et al.,
2008; Liu et al., 2009). Sperm are usually obtained after 12–18
months of treatment. Gonadotrophin treatment has been used to
induce or improve fertility in men with X-linked AHC with limited
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2003; Ozisik et al., 2003; Mantovani et al., 2006). A patient with a
mild phenotype, described by Tabarin et al.( 2000), had oligospermia
that did not respond to gonadotrophin treatment. In all the other men
treated, persistent azoospermia was observed after 6, 8, 9, 12 and
even 36 months of treatment with exogenous gonadotrophins (Semi-
nara et al., 1999; Mantovani et al., 2002; Brown et al., 2003; Ozisik
et al., 2003; Mantovani et al., 2006). In our patient, gonadotrophins
were administered for 20 months and azoospermia was found to
persist upon semen analysis. His FSH, LH and testosterone serum
levels were regularly checked and were normal, implying compliance
with gonadotrophin injections. This suggests an intrinsic role for
DAX1 in the adult human testis resulting in a defect that cannot
easily be restored by gonadotrophin treatment. However, the treat-
ment may well have allowed the development of a small number of
spermatozoa that were obtained following testicular biopsy and
used for ICSI.
In mice, targeted deletion of Dax1 (Ahch) revealed abnormalities in
testis development, in rete testis and in spermatogenesis (Park et al.,
2005). Efferent duct epithelium was hyperplastic and seminiferous
tubules were obstructed by ectopic Sertoli and Leydig cells in
adult mice (Jeffs et al., 2001). Therefore, DAX-1 is not needed for
initiating spermatogenesis but seems necessary to induce regular
spermatogenesis.
Figure 1 (A) Nonsense p.Q404X (Gln404Stop) mutation in DAX1.( B) Control sequence (arrow: nucleotide exchange). (C) The mutation, as
shown by a red star, is located in the ligand-like binding domain leading to a premature stop codon and predicted non-functional protein.
Figure 2 Seminiferous tubule sections showing (A) Sertoli cells only or an arrest of spermatogenesis at the spermatocyte stage (arrow) in most
tubules, and (B) isolated tubules with very rare spermatids (arrow). Few normal Leydig cells were seen. Magniﬁcation ×400.
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nara et al., 1999; Brown et al., 2003; Ozisik et al., 2003). The ﬁrst
biopsy reported in an adult male was performed at the age of 27, fol-
lowing 7 years of low-dose hCG treatment. It revealed
Sertoli-cell-only syndrome, rare spermatogonia and no apparent sper-
matogenesis (Seminara et al., 1999). A second report was of a
20-year-old patient after 6 months of treatment with exogenous gon-
adotrophins. This patient carried an N-terminal DAX-1 nonsense
mutation (p.Q37X) and had a milder phenotype than our patient as
he presented with adrenal insufﬁciency at the age of 20 (Ozisik
et al., 2003). The testicular biopsy revealed disorganization of the
normal tubule structure and abnormal proliferation of the interstitial
tissue as well as moderate Leydig cell hyperplasia. Interestingly, post-
mortem testicular histology from a neonate who died at 23 days has
revealed normal testicular histology (Brown et al., 2003) with the pres-
ence of well-deﬁned seminiferous testis cords containing numerous
Sertoli cells and germ cells. This suggests a potential progressive
defect in testicular function over the years.
In our patient, histology shows severe hypospermatogenesis with
most of the germ cells arrested at the spermatocyte stage. Hypos-
permatogenesis is characterized by a low, basal level of spermato-
zoid production, with most of the tubules being depleted of
mature forms of spermatozoa (Fig. 2). However, some tubules
may contain focal complete spermatogenesis that is not visible in
the thin parafﬁn section stained by hematoxylin and eosin.
However, these rare mature spermatozoa may be retrieved from
mechanically dilacerated testicular tissue. The testicular phenotype
of our patient conﬁrms data obtained in mice, suggesting that
patients with DAX1 mutations have a primary testicular defect in
addition to central HH. Our case report suggests that a testicular
biopsy should be considered if patients remain azoospermic after
gonadotrophin treatment.
Genetic counselling in couples where the man is affected by an
X-linked condition should mention that every male offspring will be
unaffected and that every female offspring will be a heterozygous
carrier of the mutation. Consequently, the risk of having an affected
male is moved to the second generation. Couples should be aware
of sex selection of embryos by preimplantation genetic diagnosis if
they wish to avoid this risk.
In conclusion, our case report gives potential hope to patients with
DAX1 mutations to father non-affected children after TESE–ICSI.
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